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Abstract
Background: Methamphetamine induces neuronal N-acetyl-aspartate synthesis in preclinical studies. In a preliminary 
human proton magnetic resonance spectroscopic imaging investigation, we also observed that N-acetyl-aspartate+N-acetyl-
aspartyl-glutamate in right inferior frontal cortex correlated with years of heavy methamphetamine abuse. In the same 
brain region, glutamate+glutamine is lower in methamphetamine users than in controls and is negatively correlated with 
depression. N-acetyl and glutamatergic neurochemistries therefore merit further investigation in methamphetamine abuse 
and the associated mood symptoms.
Methods: Magnetic resonance spectroscopic imaging was used to measure N-acetyl-aspartate+N-acetyl-aspartyl-
glutamate and glutamate+glutamine in bilateral inferior frontal cortex and insula, a neighboring perisylvian region affected 
by methamphetamine, of 45 abstinent methamphetamine-dependent and 45 healthy control participants. Regional 
neurometabolite levels were tested for group differences and associations with duration of heavy methamphetamine use, 
depressive symptoms, and state anxiety.
Results: In right inferior frontal cortex, N-acetyl-aspartate+N-acetyl-aspartyl-glutamate correlated with years of heavy 
methamphetamine use (r = +0.45); glutamate+glutamine was lower in methamphetamine users than in controls (9.3%) and 
correlated negatively with depressive symptoms (r = -0.44). In left insula, N-acetyl-aspartate+N-acetyl-aspartyl-glutamate was 9.1% 
higher in methamphetamine users than controls. In right insula, glutamate+glutamine was 12.3% lower in methamphetamine 
users than controls and correlated negatively with depressive symptoms (r = -0.51) and state anxiety (r = -0.47).
Conclusions: The inferior frontal cortex and insula show methamphetamine-related abnormalities, consistent with prior 
observations of increased cortical N-acetyl-aspartate in methamphetamine-exposed animal models and associations 
between cortical glutamate and mood in human methamphetamine users.
2 | International Journal of Neuropsychopharmacology, 2019
Keywords: methamphetamine, N-acetyl-aspartate, glutamate, abstinence, depression
Introduction
Amphetamine-type stimulants, particularly methampheta-
mine, are a rising class of abused drugs worldwide (UNODC, 
2017). With few treatment options and no approved medications 
for Stimulant Use Disorders (Courtney and Ray, 2014), continued 
investigation of the neurochemical correlates of methamphet-
amine abuse is warranted. The present study focused on the 
neurometabolites N-acetyl-aspartate (NAA) and glutamate (Glu) 
in the inferior frontal cortex and the insula, 2 perisylvian brain 
regions that show abnormalities in methamphetamine users.
NAA production, or at least expression or activity of the 
enzyme that catalyzes NAA biosynthesis, is enhanced by meth-
amphetamine in the ex vivo mouse nucleus accumbens (Niwa 
et  al., 2007), in rat pheochromocytoma-12 cells (Niwa et  al., 
2008), and in human SH-SY5Y neuroblastoma cells (Ariyannur 
et al., 2010). The NAA synthase enzyme is denoted in the litera-
ture by several names, including N-acetyltransferase, N-acetyl-
transferase-8-like protein, and shati, among others. Increase in 
the activity of this enzyme may represent an adaptive response 
to methamphetamine-induced elevation of extracellular dopa-
mine, as the enzyme appears to diminish methampheta-
mine-associated behavioral effects such as hyperlocomotion, 
sensitization, and conditioned place preference (Niwa et  al., 
2007; Ariyannur et  al., 2013). These observations and addi-
tional rodent studies intimate a more direct role for N-acetyl-
compounds in higher brain functions than had previously been 
envisioned (Ariyannur et al., 2013) and suggest novel pharmaco-
logical pathways to management of methamphetamine abuse.
In human brain, NAA is measured with 1H MRS. It is com-
monly assayed alongside N-acetyl-aspartyl-glutamate (NAAG), 
and the combined NAA+NAAG signal is abbreviated tNAA (total 
N-acetyl-compounds). Contrasting with the aforementioned 
preclinical findings, MRS has indicated below-normal tNAA 
in multiple brain regions of methamphetamine users (Ernst 
et  al., 2000; Nordahl et  al., 2002, 2005; Salo et  al., 2007, 2011a; 
Sung et al., 2007; Sailasuta et al., 2010). Because NAA and NAAG 
are abundant in neurons but not in other cells (Simmons et al., 
1991; Urenjak et al., 1992), impaired neuronal metabolic activity 
in methamphetamine users is often offered as an explanation 
of low tNAA. The relevant studies, however, overwhelmingly 
sampled methamphetamine users in mid- to long-term absti-
nence from the drug and not during active abuse or early absti-
nence. Longitudinal investigations, including studies of cerebral 
glucose metabolism (Berman et  al., 2008) and MRS (Ernst and 
Chang, 2008; Salo et al., 2011a), have shown that cortical metabo-
lism changes over the course of methamphetamine abstinence. 
Such changes could involve tNAA. In our pilot study of meth-
amphetamine users abstinent ≤2 weeks (O’Neill et  al., 2010), 
tNAA in right inferior frontal cortex correlated positively with 
duration of heavy methamphetamine abuse. Here we report on 
such effects in our full sample in inferior frontal cortex and in a 
neighboring perisylvian brain region, the insula.
 Much preclinical evidence also links methamphetamine 
with glutamatergic systems of the brain (Kalivas, 2007, 2009). 
In vivo in humans, Glu is also measured with MRS, but since 
the Glu spectrum overlaps with that of its derivative glutamine, 
the two are often assayed as a combined entity, Glx. One study 
showed no differences between methamphetamine users and 
controls in Glu or Glx in middle frontal cortex and anterior 
middle cingulate cortex (Howells et al., 2014), but others found 
differences in pregenual anterior cingulate cortex, anterior mid-
dle cingulate cortex, posterior cingulate cortex, and precuneus 
(Ernst and Chang, 2008; Crocker et al., 2014; O’Neill et al., 2014). 
In right inferior frontal cortex, Glx was lower in methampheta-
mine users than controls in a sample that overlapped with that 
of the current study (O’Neill et  al., 2014), and Glx correlated 
negatively with severity of depressive symptoms. Depression 
and other mood disorders can contribute to relapse in meth-
amphetamine abuse (Glasner-Edwards et al., 2008, 2009, 2010). 
We found no previous MRS reports of Glu or Glx in the insula 
of methamphetamine users. Glu interacts with NAA in multi-
ple ways. NAAG is biosynthesized from NAA and Glu (Becker 
et al., 2010; Collard et al., 2010) and is biodecomposed into NAA 
and Glu (Robinson et  al., 1987). NAAG colocalizes with Glu in 
synaptic vesicles (Neale et  al., 2000) and is an antagonist of 
the N-methyl-D-aspartate glutamate receptor (Sekiguchi et al., 
1989). Therefore, it is of interest to investigate MRS tNAA and 
Glx together.
 Previous studies suggested that the insula and the infe-
rior frontal gyrus show metabolical and structural abnormali-
ties in chronic methamphetamine users (London et  al., 2004; 
Thompson et al., 2004; Tabibnia et al., 2011; Morales et al., 2012), 
and neuroimaging endpoints in these regions are associated 
with affective symptoms. The insula participates in emotion 
processing (Medford and Critchley, 2010; Goerlich-Dobre et al., 
2014), and anxiety covaries negatively with glucose metabolism 
in left insula of methamphetamine users (London et al., 2004). 
The right inferior frontal gyrus has a special role in response 
inhibition (Aron et al., 2014), which is impaired in methamphet-
amine users (Monterosso et al., 2005), and in inhibitory control 
more generally (Tabibnia et al., 2011). Therefore, the insula and 
Significance Statement
Methamphetamine Use Disorder is a prevalent, treatment-resistant, public health problem. Treatment often fails during early 
abstinence from the drug, when many patients experience depression and anxiety. In the inferior frontal cortex and the insula, 
which influence negative emotions, we measured levels of N-acetyl-compounds and glutamate compounds using magnetic reso-
nance spectroscopy in methamphetamine users who had been <2 weeks abstinent and in healthy controls. Methamphetamine 
users, especially those with more years of heavy use, had higher levels of N-acetyl-metabolites than controls. Those with more 
severe depression and anxiety had lower levels of glutamate metabolites. These findings extend observations from animals and 
in vitro human cell cultures that methamphetamine increases neuronal N-acetyl aspartate concentration in living humans. They 
also motivate the development of medications that operate on N-acetyl and glutamatergic systems to assist treatment during 
early abstinence from methamphetamine.
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the inferior frontal cortex were chosen for this planned analy-
sis of tNAA and Glx in relation to methamphetamine use and 
symptoms of depression and anxiety.
Methods
Research Participants
All procedures were approved by the University of California 
Los Angeles Office for the Protection of Research Subjects. 
Participants (18–55 years old), who were recruited using Internet 
and newspaper advertisements, provided written informed con-
sent. Forty-five individuals who met criteria for methampheta-
mine dependence per DSM-IV (Table  1) and were not seeking 
treatment agreed to remain abstinent from methamphetamine 
(verified by random urine screening) while residing at a research 
unit for 2 weeks. They were compared with 45 healthy controls 
without history of substance abuse (apart from tobacco and/or 
light use of marijuana or alcohol, defined as ≤1 joint per week or 
≤10 drinks of liquor or the equivalent of beer or wine per week) 
or current use, as indicated by urine toxicology. The sample 
included here shared 42 methamphetamine and 23 control sub-
jects from a previous study (O’Neill et al., 2014) in which all the 
controls were smokers; the control group in the present report 
included almost equal numbers of smokers and nonsmokers.
Methamphetamine dependence and absence of other psy-
chiatric disorders were established using the Structured Clinical 
Interview for DSM-IV Axis I  Disorders. Heavy methampheta-
mine use was defined as using methamphetamine 3 times/wk 
or having a 2-day binge each week. Smoker status was verified 
by ≥10 ppm carbon monoxide in expired air (MicroSmokerlyzer; 
Bedfont Scientific Ltd) and the presence of urinary cotinine 
(≥200  ng/mL by Accutest NicAlert strips; JANT Pharmacal 
Corporation). The methamphetamine users were inpatients at 
the UCLA General Clinical Research Center, where they main-
tained abstinence from all drugs of abuse other than nicotine (in 
cigarettes) and caffeine (in beverages), as verified by urine toxi-
cology. Control participants visited the research site on different 
days for psychological testing and imaging. The Beck Depression 
Inventory (BDI) and the Spielberger State-Trait Anxiety Inventory 
(STAI Y1 score) were administered within 1 week of admission 
to assess depressive symptoms and state anxiety, respectively.
Magnetic Resonance Acquisition
As described in O’Neill et al. (2014), magnetic resonance spectro-
scopic imaging (MRSI) using point-resolved spectroscopy (PRESS; 
repetition-time/echo-time = 1500/30  ms, voxels 11 × 11 × 9  mm3, 
16 × 16 phase-encoding steps in-plane, 11:04-minute runt-
ime including water-suppressed and non-water-suppressed 
acquisitions) of bilateral inferior frontal cortex and insula and 
whole-brain structural MRI (MPRAGE, 1 × 1 × 1 mm3 voxels) were 
acquired at 1.5 T (Siemens Sonata, standard quadrature head 
coil). MRSI was acquired from 2 sagittal-oblique 2D slices ori-
ented parallel to the left, respectively, right temple, set ~2 cm 
deep into the brain, rotated parallel to the Sylvian fissure, and 
positioned to straddle this fissure dorsoventrally. Subject move-
ment that could have occurred between the MPRAGE and MRSI 
scans was detected by comparing head position on the MPRAGE 
to that on a structural scan acquired after MRSI; scans were 
then repeated as needed. The MRSI prescription sampled infe-
rior frontal cortex, insula, and superior temporal cortex. MRSI 
was also acquired from an axial-oblique (genu-splenium paral-
lel) slice at the level of the basal ganglia and extending from the 
caudal edge of the corpus callosum anteriorly past the corpus 
callosum splenium posteriorly (Figure  1). These regions were 
sampled at a nominal voxel size of 1.1 cc. The effective voxel 
size, however, is larger, because the voxel is modestly smeared 
by spatial apodization and the point-spread function of MRSI. 
The effective voxel size is not trivial to calculate, but using fac-
tors obtained for other MRSI techniques (Théberge et al., 2005; 
Posse et al., 2007) we estimate it at 1.3 to 1.4 cc.
Magnetic Resonance Post-Processing
MRSI was post-processed as in O’Neill et al. (2014) with minor 
update in methods for the insula. Briefly, MR spectra were fit 
automatically with LCModel yielding levels of tNAA and Glx 
normed to the unsuppressed water resonance and expressed 
in Institutional Units (IU). Each MPRAGE was segregated in 
ICBM152 space into gray matter, white matter, and CSF subvol-
umes using SPM (http://www.fil.ion.ucl.ac.uk/spm/software/). 
The subvolumes were brought back into native space using the 
inverse of the MPRAGE-to-ICBM152 transform. Inferior frontal 
cortex MRSI voxels were selected manually as in O’Neill et al. 
(2014). For the insula, MRSI voxel selection was automated with 
the help of binary masks of left and right insula generated from 
the MPRAGE by FreeSurfer (https://surfer.nmr.mgh.harvard.
edu/) in ICBM152 space. Again, masks were restored to native 
space with the inverse transform. Then, for both inferior frontal 
cortex and insula, using custom-written software, the MPRAGE, 
tissue subvolumes, and masks were aligned with each MRSI 
slice; the tissue-composition of each MRSI voxel was calculated; 
MRSI voxels were retained with >50% overlap with the target 
brain region (exclusive of CSF); and neurometabolite levels were 
corrected for voxel CSF content. Typically for all 4 brain regions 
and all 3 subject groups, 1 to 4 voxels per region passed all 
Table 1. Characteristics of Research Participants
Methamphetamine 
(n = 45) Control (n = 45) P
Sex .99
 Female 24 23
 Male 21 22
Age, y 33.0 ± 9.3 32.9 ± 8.6 .94
Education, y 11.8 ± 2.3 13.5 ± 1.8 <.0005
Depression, BDI Score 15.6 ± 13.0 2.3 ± 2.8 <.0005
Anxiety, STAI Y1 Score 33.1 ± 9.8 27.0 ± 7.4 .002
Cigarette smoking
 Smokers, n 41 23 <.0005
 Pack-years tobacco 
(smokers only)
11.7 ± 11.4 9.7 ± 7.9 .42
 Fagerström Score 
(smokers only)
3.4 ± 2.1 3.6 ± 2.1 .78
Methamphetamine use
 Duration of use, y 11.1 ± 7.8 0 ± 0 —
 Duration of heavy 
use, y
6.7 ± 6.4 0 ± 0 —
 Current use, g/wk 2.0 ± 1.4 0 ± 0 —
Marijuana use
 Marijuana users, n 27 4 <.0005
 Current use, d/month 5.5 ± 9.2 0.2 ± 0.8 <.0005
Shown are numbers of participants or group means ± SDs. P values are for Χ2 
(sex, number of smokers, number of marijuana users) or 2-way independent t 
tests (all other variables), unless otherwise indicated for comparisons of the full 
methamphetamine to the full control sample.
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quality-control criteria and were included in the subject’s aver-
age for that region. Thus, differences in voxel sampling were 
unlikely to have affected results and—given the strict quality-
control criteria, the voxel size relative to region volume, and the 
substantial local tissue content of voxels—the spectrum of even 
one voxel was deemed sufficient to represent a region.
Correction for Differences in MRSI Voxel 
Tissue-Composition
The group-mean volume fraction of gray matter, white matter, 
and CSF in MRSI voxels did not differ significantly between the 
2 samples, except in the right insula, where the volume fraction 
of CSF was slightly (12% vs 14%) but significantly lower in meth-
amphetamine users than in controls (P = .030, independent t test). 
MRSI neurometabolite levels were corrected for voxel CSF content 
to adjust for any such differences. Voxel white matter content was 
trendwise (P = .088) lower (3% vs 4%) while gray matter content 
was slightly higher (86% vs 84%; P = .052) in methamphetamine 
users; therefore, gray and white matter content were included as 
covariates in the relevant analyses to adjust for such differences.
Statistical Analyses
MRSI voxels within the PRESS excitation volume with ≥50 vol-
ume% of each target region were retained. Spectra with linewidth 
>0.10 ppm, signal-to-noise ratio <5, or not passing operator inspec-
tion were discarded, as were metabolite signals with Cramer-Rao 
Lower Bounds >20%. Metabolite data passing the foregoing quality-
control criteria were averaged together for each subject to obtain a 
representative value for each metabolite region combination (e.g., 
tNAA in left insula). These quality control measures resulted in 
data from different numbers of participants contributing to the 
various analyses across regions and metabolites (Table 2).
Group differences in mean clinical endpoints were exam-
ined with independent t tests. Between-group differences 
in regional metabolite levels were tested using ANCOVA, 
Bonferroni-corrected for multiple comparisons. Covariates 
included age, sex, tobacco-smoking status, marijuana use sta-
tus, and white mater and gray matter content. Given potential 
effects of tobacco use on neuroimaging endpoints, particularly 
in the insula (Morales et al., 2014; Naqvi et al., 2014), significant 
between-group differences in metabolite levels were retested 
comparing methamphetamine users with control smokers 
and control nonsmokers separately using independent t tests. 
Within-group relationships between regional metabolites and 
years of heavy methamphetamine abuse, BDI Score, and STAI 
Y1 Score were examined with Pearson correlation, Bonferroni-
corrected for multiple comparisons. Significant findings were 
retested as Spearman correlations, partialling out demographic, 
clinical, or tissue content variables that may have significantly 
affected the metabolite level in question. Spearman rather than 
Pearson partial correlation was chosen, since the former is more 
conservative, less biased by outliers, and does not a priori pre-
sume linearly related and normally distributed variables. Based 
on our pilot study (O’Neill et  al., 2010), we hypothesized that 
tNAA would be higher in the methamphetamine-dependent 
vs control subjects and/or would be correlated positively with 
years of heavy methamphetamine abuse in one or more perisyl-
vian regions. The criterion for statistical significance was P < .05, 
whereby in cases with Bonferroni-correction the raw P value 
was multiplied by the number of multiple comparisons.
Results
Sample Characteristics
The methamphetamine users and controls were well matched 
for sex and age (Table 1), although the methamphetamine users 
had approximately 2 fewer years of education than controls on 
average (P < .0005) and most smoked cigarettes, whereas about 
one-half of the controls were smokers. Lifetime tobacco expo-
sure (pack-years) and current tobacco dependence (Fagerström 
Score) did not differ significantly between smokers in the two 
groups. Although both groups reported light marijuana use, the 
methamphetamine users reported more (P < .0005); therefore, 
marijuana use was included as a covariate in between-group 
comparisons. The groups differed on self-reports of mood. The 
mean BDI score was ~6× higher (P < .0005, independent t test), 
and state anxiety was 23% higher (P = .002) in the methampheta-
mine users than controls.
Regional Neurometabolite Levels
Across the various comparisons, the number of subjects per group 
with data passing quality control varied from 31 to 44 (Table 2). 
Figure 1. (A) sagittal-oblique T1-weighted MRI of the brain showing sample coregistration of FreeSurfer right insula volume-of-interest (yellow-red) with superim-
posed right perisylvian 1H magnetic resonance spectroscopic imaging (MRSI) point-resolved spectroscopy (PRESS) excitation volume (“slice,” white rectangle). A simi-
lar sagittal-oblique PRESS slice sampled the left insula. (B) Overlap of the right insula volume with a third, axial-oblique PRESS slice. The opposite side of this slice 
cosampled the left insula. Each slice was 9 mm thick and consisted of a rectangular in-plane array of 11 × 11 mm2 voxels (green grids). (C) Sample right perisylvian 
MRSI spectrum showing high-amplitude, low-noise, well-separated peaks for the target neurometabolites N-acetyl-aspartate+N-acetyl-aspartyl-glutamate (tNAA) and 
glutamate+glutamine (Glx).
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In left insula, tNAA was 9.1% higher in the methamphetamine 
than the control sample (Bonferroni-corrected P = .0064, ANCOVA 
covarying sex, age, smoking status, marijuana status, and gray 
and white matter). Of the 31 subjects with passing data quality in 
this region, 23 (74.2%) had tNAA values greater than the control 
mean. This difference remained significant when the metham-
phetamine users were compared separately with the smoking 
(8.8% higher; P = .019, independent t test) and nonsmoking (10.0% 
higher; P = .038) controls (Figure 2). The difference in tNAA, com-
paring the methamphetamine and total control samples, also 
remained significant when BDI score was added as a covariate 
(Bonferroni-corrected P = .004, ANCOVA). Although they were in 
no identifiable way atypical of the sample and none had a tNAA 
level ≥4 SDs above the mean of the remaining sample (a com-
monly used criterion for outliers), group-mean tNAA was still 
higher for methamphetamine than for control subjects at trend 
level (P = .086) when the 3 methamphetamine subjects with high-
est tNAA in this region were removed on an exploratory basis. 
When the full samples were compared using nonparametric sta-
tistics (less sensitive to outliers), tNAA was significantly higher 
for methamphetamine than for control subjects (P = .023). There 
were no significant group differences in tNAA in other regions.
Table 2. Levels of tNAA and Glx in Perisylvian Cortices
Left Inferior Frontal Cortex Right Inferior Frontal Cortex
Methamphetamine Control Methamphetamine Control
tNAA 8.2 ± 1.2 8.1 ± 1.0 8.2 ± 1.0 8.2 ± 0.9
Participants 41 44 37 41
Glx 12.4 ± 2.2 12.8 ± 2.2 12.7 ± 2.5* 14.0 ± 2.4
Left insula Right insula
Methamphetamine Control Methamphetamine Control
tNAA 8.4 ± 1.3** 7.7 ± 0.9 7.8 ± 1.0 8.1 ± 2.1
Participants 31 31 37 37
Glx 9.8 ± 2.7 9.3 ± 2.0 9.3 ± 2.0* 10.6 ± 3.5
Indicated are numbers of participants with usable MRSI data for each metabolite in each target brain region.
tNAA and Glx levels are group means ± SD in IU, corrected for voxel CSF content.
Significant between-group comparisons in bold (*P < .05, **P < .01 Bonferroni-corrected for multiple comparisons, ANCOVA covarying for age, sex, tobacco-smoking sta-
tus, marijuana use status, and white and gray matter content).
Figure 2. (A) CSF-corrected levels of N-acetyl-aspartate+N-acetyl-aspartyl-glutamate (tNAA) (NAA+NAAG) in Institutional Units (IU) in left insula of methamphetamine 
users (MA), control smokers, and control nonsmokers. Horizontal bars denote group means. *P < .05 for difference between the methamphetamine users and controls 
by independent t test. (B) Associations of tNAA in right inferior frontal cortex vs years of heavy methamphetamine use. P = .032, Pearson with Bonferroni correction. 
P = .047, (r = +0.34, Spearman) when effects of age, BDI Score, and pack-years of smoking were partialled out. (C–D) Negative associations of right insula glutamatergic 
compounds with symptoms of depression and anxiety in methamphetamine users. Y axes indicate CSF-corrected levels of Glx (Glu+ glutamine) in Institutional Units 
(IU). Depressive symptoms were self-reported using the Beck Depression Inventory (BDI), and state anxiety was self-reported using the Spielberger State-Trait Anxiety 
Inventory. P < *.05, ***.0005, Spearman with Bonferroni correction, partialling sex, age, smoking status, marijuana status, and gray and white matter.
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Glx was significantly lower in the right inferior cortex (9.3% 
lower; Bonferroni-corrected P = .004, ANCOVA covarying sex, 
age, smoking status, marijuana status, and gray and white mat-
ter) and in the right insula (12.3% lower; Bonferroni-corrected 
P = .0004) in methamphetamine users than in controls (Table 2). 
There were no significant between-group differences in Glx in 
other regions.
There was a significant main effect of sex on Glx in left 
insula (P = .048), whereby Glx was 13.4% higher in males than 
in females. As indicated, groups were well balanced for sex 
(Table 1) and sex was included as a covariate in statistical analy-
ses. There were no significant main effects of marijuana use sta-
tus on regional metabolites.
Correlations of tNAA with Duration of 
Methamphetamine Abuse
In right inferior frontal cortex, tNAA correlated positively with 
years of heavy methamphetamine abuse (r = +0.43, Bonferroni-
corrected P = .032, Pearson; Figure 2). This association remained 
significant when partialling age, BDI Score, and pack-years of 
smoking (r = +0.39, P = .047, Spearman). tNAA also correlated 
positively with years of any methamphetamine abuse, but this 
result did not survive Bonferroni correction. There were no sig-
nificant correlations of tNAA with duration of heavy metham-
phetamine abuse in other regions or correlations of Glx with 
duration of heavy methamphetamine abuse in any region.
Correlations of Neurometabolite Levels with 
Symptoms of Depression and Anxiety
There were no significant associations of tNAA with BDI Score 
or STAI Y1 Score. Glx was negatively correlated with BDI Score 
in right inferior frontal gyrus (r = -0.51, Bonferroni-corrected 
P = .0052, Spearman, partialling sex, age, smoking status, mari-
juana status, and gray and white matter) and right insula 
(r = -0.44, Bonferroni-corrected P = .0004, partialling sex, age, 
smoking status, marijuana status, and gray and white matter). 
In right insula, Glx was additionally significantly negatively 
correlated with STAI Y1 Score (r = -0.47, Bonferroni-corrected 
P = .024, Spearman, partialling sex, age, smoking status, mari-
juana status, and gray and white matter).
Discussion
This study yielded 3 major findings: (1) tNAA in methampheta-
mine users was moderately elevated in the left insula and in 
the right inferior frontal cortex tNAA was positively correlated 
with years of heavy methamphetamine exposure; (2) in the right 
inferior frontal cortex and right insula, Glx was lower in meth-
amphetamine users; and (3) in those regions, Glx was negatively 
correlated with severity of depression and anxiety symptoms 
in methamphetamine users. Thus, chronic methamphetamine 
users exhibit modest increments in regional cortical tNAA lev-
els, similar to those observed in ex vivo and in vitro systems. 
Results also support previous findings associating the mood 
symptoms of early methamphetamine abstinence with gluta-
matergic metabolism.
Mean tNAA was greater than the control mean in one brain 
region of methamphetamine abusers, and tNAA correlated 
with duration of heavy methamphetamine exposure in another 
region. These effects remained significant after accounting for 
age, tobacco smoking, MRSI voxel tissue-composition, and BDI 
Score, and for multiple comparisons. Possible explanations 
include stimulation of NAA synthase by methamphetamine as 
in preclinical models (Niwa et al., 2007, 2008; Ariyannur et al., 
2010), deceleration of NAA degradation, and (possibly unto-
ward) neuroplastic increase in neuronal mass or metabolic 
activity, and others. Noninvasive in vivo human proton MRS 
is not capable of distinguishing among these various mecha-
nisms, which are also not mutually exclusive. The tNAA effect 
was small, comprising an approximately 10% group-mean dif-
ference (left insula) and a 0.07 IU/y increment (right inferior 
frontal cortex) and was not statistically significant in all regions 
tested. Although significant effects on the order of 5% to 15% 
are common in MRS studies of brain N-acetyl- (and glutamater-
gic) compounds in methamphetamine abuse (Ernst et al., 2000; 
Nordahl et al. 2002; Salo et al., 2007, 2011a, 2011b; Sailasuta et al., 
2010; Cloak et al., 2011; Crocker et al., 2014; Howells et al., 2014), 
the subtlety of the present tNAA effects may reflect superim-
position of tNAA elevation from methamphetamine on tNAA 
declines due to aging (Aoki et al., 2012), chronic cigarette smok-
ing (Durazzo et al., 2016), or other factors. That tNAA correlated 
with duration of heavy (as opposed to any) methamphetamine 
abuse is consistent with in vitro observations that methamphet-
amine significantly increased NAA only at higher methamphet-
amine doses (Ariyannur et al., 2010). Overall, these results are 
consistent with a gradual rise in tNAA with continuing metham-
phetamine exposure, perhaps as an adaptation to excess dopa-
mine signaling (Niwa et al., 2007). It is recommended that tNAA 
in early abstinence from methamphetamine be reinvestigated 
for verification in further samples and at high-field strength.
Prior studies of methamphetamine users documented 
below-normal tNAA in some brain regions (Ernst et  al., 2000; 
Nordahl et  al., 2002, 2005; Salo et  al., 2007, 2011a; Sung et  al., 
2007; Sailasuta et al., 2010). Rather than inferior frontal cortex 
and insula, as sampled here, these studies interrogated other 
brain regions (pregenual anterior and anterior middle cingulate 
cortices, prefrontal white matter, caudate-putamen, occipital 
cortex, and dorsal posterior cingulate cortex) than those exam-
ined here. Moreover, participants in those studies had been 
abstinent from methamphetamine for more than the 2-week 
maximum in this study. Methamphetamine effects on tNAA 
may vary with brain region or duration of abstinence. In early 
abstinence, tNAA elevations in compensation to dopaminergic 
hyperactivation due to methamphetamine may predominate 
in certain regions over tNAA decreases from neuronal loss or 
impairment. In mid-term abstinence, the former effect may 
fade leading the latter effects to predominate. Finally, in late 
abstinence rise of tNAA may be observed with recovery of func-
tion by some neurons (Salo et al., 2011a). Although, if metham-
phetamine enhances NAA production, one might anticipate a 
decrease in NAA production during abstinence due to removal 
of the enhancing factor; it may take time, especially after years 
of methamphetamine abuse as in our sample, for such decrease 
to become detectable. Hence, present tNAA observations may, in 
some aspects, reflect “overhang” from the chronic state of active 
abuse rather than acute changes precipitated by abstinence.
Inflammatory processes may influence MRS neurometabo-
lite levels (Chang et al., 2013) and the evolution of brain metabo-
lism during recovery from methamphetamine abuse (Volkow 
et al., 2001; Berman et al., 2008). We previously suggested that 
higher cortical tNAA in early abstinence from methampheta-
mine could be due to local invasion of microglia as part of the 
inflammatory response (O’Neill et  al., 2010), since activated 
microglia contain high concentrations of NAAG (Passani et al., 
1998). NAA itself, moreover, acts as an antiinflammatory agent 
for reactive astroglia (Rael et al., 2004). Hence, an inflammatory 
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response in early abstinence could initiate a transient rise in 
tNAA levels. Longitudinal cortical MRS measurements may help 
answer such questions.
Findings also included Glx approximately 10% lower in right 
inferior frontal cortex and insula in methamphetamine users 
and that Glx in these regions was negatively correlated with 
depression and anxiety. The findings in right inferior frontal 
cortex largely replicated those in O’Neill et al. (2014), which had 
essentially the same methamphetamine sample. However, the 
control sample in the present analysis was now as large as the 
methamphetamine sample, rather than being about one-half 
the size. The present study extends findings to the neighbor-
ing right insula, where a negative relation of Glx with anxiety 
was also found. As discussed in O’Neill et al. (2014), depression 
appears to be associated with glutamatergic systems and with 
the right forebrain. Glutamatergic agents might offer promise 
in combatting the often severe depressive symptoms of early 
abstinence from methamphetamine (Zorick et al., 2011). Present 
findings also motivate exploration of MRS Glx as a potential bio-
marker of relapse in methamphetamine abuse in systematic 
clinical trials.
Overall, the current findings add to evidence pointing to 
(especially right) inferior frontal cortex and insula as sites of 
sequelae of methamphetamine abuse (London et  al., 2004; 
Thompson et al., 2004; Tabibnia et al., 2011; Morales et al., 2012; 
O’Neill et al., 2014; Okita et al., 2016). That the major findings were 
hemispherically lateralized is not surprising, as functional later-
alization within perisylvian cortices is well known. Prominent 
examples include lateralization of language (Ojemann, 1991), 
mood symptoms following cerebrovascular insult (Starkstein 
et al., 1989; Morris et al., 1996), and motor response inhibition 
(Aron et  al., 2014). In fact, a possible alternative explanation 
of our Glx findings in right inferior frontal cortex and insula 
(Table 2) is that controls have a higher Glx on the right side, per-
haps reflecting functional lateralization that does not pertain in 
the methamphetamine subjects. We have previously observed 
effects on glucose metabolism lateralized to the left insula in 
methamphetamine abuse (London et  al., 2004). It remains a 
challenge of neuroimaging research to delineate more fully the 
course, character, and extent of methamphetamine-associated 
neurophysiological effects on these regions and their possible 
role in therapeutic response.
This investigation had limitations including MRS acquisition 
at 1.5 T. Studies at 3 T would yield larger and better separated 
metabolite signals. Acquisition at ultrahigh-field (e.g., 7 T) would 
further enable separation of the NAA and NAAG components of 
the tNAA signal. In addition, cross-sectional, rather than longi-
tudinal, data were used. As is common in studies of stimulant 
abuse, marijuana use was much more prevalent in the meth-
amphetamine than in the control sample, representing a poten-
tial confound. Marijuana use status, however, did not affect 
regional metabolite endpoints and was included as a statistical 
covariate. These weaknesses are balanced by certain strengths, 
including: high spatial resolution (nominally approximately 1.1 
cc, effectively approximately 1.3–1.4 cc) of MRSI; a rarely used 
sagittal-oblique MRSI prescription to access inferior frontal cor-
tex and insula; water-referenced neurometabolite levels rather 
than ratios to creatine+phosphocreatine; determination of MRSI 
voxel tissue composition and its use in quantitation; a well-char-
acterized methamphetamine user sample in recent abstinence 
from drug; samples fairly well matched for sex; and considera-
tion of tobacco smoking. The tNAA findings represent a possible 
human in vivo expression of methamphetamine effects previ-
ously observed only preclinically, and the Glx findings reinforce 
notions of a possible glutamatergic basis for the mood symp-
toms of early abstinence from methamphetamine.
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